Oral JAK inhibitors are preferred first-line long-term therapy for severe adult AA; FDA-approved agents are favored, whereas dupilumab is an alternative for patients with comorbid atopy. Experts ...
The share of support for each candidate in the 15 most recent polls. About this data Note: The candidates shown are those who have gained the most support in recent polls. Some polls didn’t include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results